<DOC>
	<DOCNO>NCT01118728</DOCNO>
	<brief_summary>Primary Objective : - To assess long term safety Sarilumab ( SAR153191/REGN88 ) patient ankylose spondylitis ( AS ) Secondary Objective : - To assess long term efficacy Sarilumab ( SAR153191/REGN88 ) patient AS</brief_summary>
	<brief_title>Extension Study Long Term Evaluation SAR153191 ( REGN88 ) Patients With Ankylosing Spondylitis</brief_title>
	<detailed_description>The maximum study duration per participant 267 week ( approximatively 5 year ) break follow : - screen maximum 1 week ; - treatment maximum 260 week ; - follow-up 6 week treatment discontinuation .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<criteria>Inclusion criterion : Patient AS participate complete 12week treatment study DRI11073NCT01061723 . Exclusion criterion : Adverse event ( ) lead treatment discontinuation DRI11073 study ; Event laboratory abnormality observe last treatment visit DRI11073 study would adversely affected participation patient study per investigator judgment . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>